UnitedHealth Group (UNH) is back in focus after the stock recently outperformed major indexes as investors weigh the company’s expanded 2027 Medicare Advantage lineup and earnings expectations ahead of its October 13 report.

Recent trading tells a mixed story. UnitedHealth Group’s share price is up 10.55% year to date, yet the 30 day share price return is down 6.36% and the 90 day share price return is down 11.03%. At the same time, the 3 year total shareholder return is down 24.54%, suggesting that near term optimism around the Medicare Advantage expansion and earnings expectations contrasts with weaker longer run holding period results.

Spot similar healthcare stories with earnings and product catalysts in our hand picked 35 healthcare AI stocks that could be setting up for their next move.

UnitedHealth Group now trades well below both analyst targets and one intrinsic value estimate, creating a wide valuation gap after a choppy few months. The key issue is where fair value actually lands within that range.

Most Popular Narrative: 23% Undervalued

On the most followed view, UnitedHealth Group screens as undervalued, with a fair value estimate of $481.72 against the recent close near $371.90. This puts the focus squarely on whether the long term earnings story holds up.

UnitedHealth Group is still working through unanticipated changes in Medicare membership profiles by pushing complex patients into clinical and value-based programs. This approach is intended to support more durable plan designs and future revenue and earnings.

The company continues to invest in technology that improves physician workflows and digital engagement. The current AI program targets billions of dollars of G&A savings through automation of claims, call handling, clinical documentation and back-office functions, and is aimed at lifting net margins and operating earnings over time.

See why 663 investors see UnitedHealth Group as 23% undervalued.

Result: Fair Value of $481.72 (UNDERVALUED)

Still, that valuation gap for UnitedHealth Group only holds if commercial medical cost trends and pressured Medicaid profitability do not erode margins faster than expected.

Find out about the key risks to this UnitedHealth Group narrative.

Next Steps

Curious whether the mixed sentiment around UnitedHealth Group lines up with your own view? Act quickly, review both sides of the story, and weigh the 5 key rewards and 1 important warning sign.

Looking for more investment ideas beyond UnitedHealth Group?

If UnitedHealth Group has sharpened your focus, do not stop here. Broader context across sectors and styles can help you stress test your convictions fast.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include UNH.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com